The failure of clinical trials to treat primary progressive MS with the PDE4 inhibitor rolipram suggests that other PDE families, such as PDE8, expressed in Teff cells might be important for controlling their pro-inflammatory function. This evidence concerns the gene PDE4A and myeloid sarcoma.